
The PepGNP-Covid19 vaccine, a gold nanoparticle-based T cell vaccine, proved safe and immunogenic in a phase 1 trial. No serious adverse events were reported, and strong CD8+ T cell responses were seen, especially in memory subsets. This promising vaccine approach may offer broader, long-lasting protection against SARS-CoV-2 and reduce immune escape risks.
Like
Save
Share